Faculty, Staff and Student Publications
Publication Date
1-1-2023
Journal
Technology in Cancer Research & Treatment
Abstract
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related deaths worldwide. In China, most HCC patients are diagnosed with advanced disease and in these cases surgery is challenging. Conversion therapy can be used to change unresectable HCC into resectable disease and is a potential breakthrough treatment strategy. The resection rate for unresectable advanced HCC has recently improved as a growing number of patients have benefited from conversion therapy. While conversion therapy is at an early stage of development, progress in patient selection, optimum treatment methods, and the timing of surgery have the potential to deliver significant benefits. In this article, we review the current evidence and clinical experience of conversion therapy in HCC. General conversion modalities such as systemic treatments (systemic chemotherapy, targeted therapy, or immunotherapy), locoregional therapy (transarterial chemoembolization, hepatic arterial infusion chemotherapy, or selective internal radiation therapy), and combination therapy were summarized. We also discuss the current challenges of conversion therapy and provide identify areas for future research to improve the development of conversion therapy in advanced HCC.
Keywords
Humans, Carcinoma, Hepatocellular, Chemoembolization, Therapeutic, Liver Neoplasms, Combined Modality Therapy, Immunotherapy, hepatocellular carcinoma, conversion therapy, surgery, review
DOI
10.1177/15330338231159718
PMID
36855803
PMCID
PMC9983081
PubMedCentral® Posted Date
February 2023
PubMedCentral® Full Text Version
Post-Print
Published Open-Access
yes
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Data Science Commons, Health Information Technology Commons, Oncology Commons, Surgery Commons
